Subcutaneous Cladribine Plus Pegylated Interpheron Alfa-2a in Advanced Systemic Mastocytosis With D816V and Other Exon 17 KIT Mutations.

Trial Profile

Subcutaneous Cladribine Plus Pegylated Interpheron Alfa-2a in Advanced Systemic Mastocytosis With D816V and Other Exon 17 KIT Mutations.

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 12 Sep 2016

At a glance

  • Drugs Cladribine (Primary) ; Peginterferon alfa-2a (Primary)
  • Indications Leukaemia; Sarcoma; Systemic mastocytosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Aug 2016 Planned primary completion date changed from 1 Mar 2013 to 1 Feb 2017.
    • 26 Aug 2016 Planned End Date changed from 1 May 2013 to 1 Jun 2017.
    • 20 Jul 2013 New source identified and integrated (European Clinical Trials Database; EudraCT2012-000797-35).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top